Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should You Hold Quest Diagnostics Stock in Your Portfolio for Now?
DGX pushes growth through acquisitions and advanced diagnostics even as rising debt and tough competition pressure its outlook.
Quest Diagnostics (DGX) Up 2.6% Since Last Earnings Report: Can It Continue?
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?
Quest Diagnostics Incorporated (DGX) Presents at 7th Annual Healthcare Symposium Transcript
Quest Diagnostics Incorporated ( DGX ) 7th Annual Healthcare Symposium November 14, 2025 8:50 AM EST Company Participants Asia Chang Conference Call Participants Kevin Dreyer - GAMCO Investors, Inc. Carri Chan David Harding Noam Krantz - Guardant Health, Inc. Alexis Tosti Presentation Kevin Dreyer GAMCO Investors, Inc. Okay. I want to welcome everyone to our 7th Annual Healthcare Symposium jointly sponsored by Gabelli Funds and Columbia Business School.
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics (DGX) is a Top-Ranked Growth Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Quest Diagnostics Incorporated (DGX) Q3 2025 Earnings Call Transcript
Quest Diagnostics Incorporated (NYSE:DGX ) Q3 2025 Earnings Call October 21, 2025 8:30 AM EDT Company Participants Shawn Bevec - Vice President of Investor Relations James Davis - Chairman, CEO & President Sam Samad - Executive VP & CFO Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division Michael Cherny - Leerink Partners LLC, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Kevin Caliendo - UBS Investment Bank, Research Division Jack Meehan - Nephron Research LLC Luke Sergott - Barclays Bank PLC, Research Division David Westenberg - Piper Sandler & Co., Research Division Erin Wilson Wright - Morgan Stanley, Research Division Andrew Brackmann - William Blair & Company L.L.C., Research Division Michael Ryskin - BofA Securities, Research Division Pito Chickering - Deutsche Bank AG, Research Division Tycho Peterson - Jefferies LLC, Research Division Eric Coldwell - Robert W.
Quest Diagnostics Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
DGX posts a strong Q3 with revenues and EPS beating estimates, higher margins and an upbeat full-year outlook.
Quest Diagnostics (DGX) Surpasses Q3 Earnings and Revenue Estimates
Quest Diagnostics (DGX) came out with quarterly earnings of $2.6 per share, beating the Zacks Consensus Estimate of $2.51 per share. This compares to earnings of $2.3 per share a year ago.
Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings
DGX is poised for solid Q3 2025 results, backed by strong DIS growth, strategic M&A and robust test demand across key health segments.
